The General Hospital Corporation Patent Portfolio Statistics

The General Hospital Corporation

Profile Summary

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of The General Hospital Corporation look like?

Total Applications: 2,739
Granted Patents: 1,433
Grant Index 65.98 %
Abandoned/Rejected Applications: 739 (34.02%)
In-Process Applications: 563
Average Grant Time: 3.29 Years
Average Office Actions: 2.03

Which Technology Area The General Hospital Corporation is filing most patents in? (Last 10 years)

Art Unit Definition Total Applications
Opap Parked GAU 129
1618 Organic Compounds: Bio-affecting, Body Treating, Drug Delivery, Steroids, Herbicides, Pesticides, Cosmetics, and Drugs 87
1632 Molecular Biology, Bioinformatics, Nucleic Acids, Recombinant DNA and RNA, Gene Regulation, Nucleic Acid Amplification, Animals and Plants, Combinatorial/ Computational Chemistry 80
1634 Molecular Biology, Bioinformatics, Nucleic Acids, Recombinant DNA and RNA, Gene Regulation, Nucleic Acid Amplification, Animals and Plants, Combinatorial/ Computational Chemistry 80
1647 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 78

How many patents are The General Hospital Corporation filing every year?

Year Total Applications
2022 0*
2021 78*
2020 142
2019 171
2018 199

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of The General Hospital Corporation in USPTO?

Publication number: US20220017883A1
Application number: 17/450,588

Abstract:
Engineered CRISPR from Prevotella and Francisella 1 (Cpf1) nucleases with altered and improved target specificity and their use in genomic engineering, epigenomic engineering, genome targeting, genome editing, and in vitro diagnostics.

Publication date: 2022-01-20
Applicant: The General Hospital Corporation
Inventors: J Joung Keith


Publication number: US20220025347A1
Application number: 17/450,593

Abstract:
Engineered CRISPR from Prevotella and Francisella 1 (Cpf1) nucleases with altered and improved target specificity and their use in genomic engineering, epigenomic engineering, genome targeting, genome editing, and in vitro diagnostics.

Publication date: 2022-01-27
Applicant: The General Hospital Corporation
Inventors: Benjamin Kleinstiver


Publication number: US20220002400A1
Application number: 17/484,995

Abstract:
Methods of treating influenza A are provided, comprising administering to a subject at least one agent selected from a WDR7 inhibitor, a CCDC115 inhibitor, a TMEM199 inhibitor, and a CMTR1 inhibitor.

Publication date: 2022-01-06
Applicant: The General Hospital Corporation
Inventors: Baillie J Kenneth


How are The General Hospital Corporation’s applications performing in USPTO?

Application Number Title Status Art Unit Examiner
17/450,588 Variants Of Crispr From Prevotella And Francisella 1 (Cpf1) OPAP Central, Docket
17/450,593 Variants Of Crispr From Prevotella And Francisella 1 (Cpf1) OPAP Central, Docket
17/484,995 Methods Of Treating Influenza A Virus Infections Application Undergoing Preexam Processing 1643
17/448,463 Half-Curcuminoids As Amyloid-Beta Pet Imaging Agents Docketed New Case – Ready for Examination OPAP Central, Docket
17/480,924 Half-Curcuminoids As Amyloid-Beta Pet Imaging Agents Docketed New Case – Ready for Examination OPAP Central, Docket